Back to top
more

Arcus Biosciences (RCUS)

(Delayed Data from NYSE)

$18.09 USD

18.09
442,554

-0.28 (-1.52%)

Updated Oct 14, 2024 04:00 PM ET

After-Market: $18.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 1.77% and 2.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q3 Earnings Expected to Decline

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for October 15th

BWB, CDE, ONEM, RCUS, and TMHC have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2021

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Lags Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -41.56% and -48.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Arcus Biosciences, Inc. (RCUS) Report Negative Q2 Earnings? What You Should Know

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcus Biosciences, Inc. (RCUS) Stock Jumps 15.5%: Will It Continue to Soar?

Arcus Biosciences, Inc. (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -52.11% and -49.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (RCUS) Stock Jumps 9.5%: Will It Continue to Soar?

Arcus Biosciences, Inc. (RCUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Orchard (ORTX) Gets FDA's RMAT Status for Gene Therapy in MLD

The FDA bestows a Regenerative Medicine Advanced Therapy status on Orchard Therapeutics' (ORTX) investigational gene therapy, OTL-200, for treating early-onset metachromatic leukodystrophy. Shares up.

Affimed (AFMD) Catches Eye: Stock Jumps 8.8%

Affimed (AFMD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity

bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.

Moleculin Biotech (MBRX) Jumps: Stock Rises 8.5%

Moleculin Biotech (MBRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Zosano Pharma (ZSAN) in Focus: Stock Moves 6.3% Higher

Zosano Pharma (ZSAN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Exact Sciences (EXAS) Soars: Stock Adds 9.8% in Session

Exact Sciences (EXAS) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Are Options Traders Betting on a Big Move in Arcus Biosciences (RCUS) Stock?

Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.

Infinity's Eganelisib Gets Fast Track Tag for Breast Cancer

Infinity's (INFI) eganelisib, combined with a checkpoint inhibitor and chemotherapy, gets Fast Track designation by the FDA for the treatment of inoperable locally-advanced or metastatic TNBC in the first-line setting.

Gilead Expands Collaboration With Tango for Cancer Therapies

Gilead (GILD) expands its partnership with biotech company, Tango, for innovative targeted immune evasion cancer therapies.

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Has Arcus Biosciences (RCUS) Outpaced Other Medical Stocks This Year?

Is (RCUS) Outperforming Other Medical Stocks This Year?

Is Arcus Biosciences (RCUS) Stock Outpacing Its Medical Peers This Year?

Is (RCUS) Outperforming Other Medical Stocks This Year?

Gilead's Rating Upgraded on Potential Coronavirus Drug Sales

Gilead (GILD) rides high on potential sales from its experimental coronavirus treatment, remdesivir, and collaboration with Arcus.

Arcus Biosciences (RCUS) Catches Eye: Stock Jumps 5.4%

Arcus Biosciences (RCUS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Gilead Inks 10-Year Deal With Arcus for Immuno-oncology Drugs

Gilead (GILD) looks to expand presence in the immune-oncology space with a 10-year partnership with Arcus.

Infinity (INFI) Q1 Earnings Lag Estimates, IPI-549 in Focus

Infinity (INFI) posts a wider-than-expected loss for the first quarter of 2020.

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Misses Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -12.50% and -12.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?